281 related articles for article (PubMed ID: 27005768)
1. Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia.
Kojima S; Matsui K; Ogawa H; Jinnouchi H; Hiramitsu S; Hayashi T; Yokota N; Kawai N; Tokutake E; Uchiyama K; Sugawara M; Kakuda H; Wakasa Y; Mori H; Hisatome I; Waki M; Ohya Y; Kimura K; Saito Y;
J Cardiol; 2017 Jan; 69(1):169-175. PubMed ID: 27005768
[TBL] [Abstract][Full Text] [Related]
2. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.
Kojima S; Matsui K; Hiramitsu S; Hisatome I; Waki M; Uchiyama K; Yokota N; Tokutake E; Wakasa Y; Jinnouchi H; Kakuda H; Hayashi T; Kawai N; Mori H; Sugawara M; Ohya Y; Kimura K; Saito Y; Ogawa H
Eur Heart J; 2019 Jun; 40(22):1778-1786. PubMed ID: 30844048
[TBL] [Abstract][Full Text] [Related]
3. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
[TBL] [Abstract][Full Text] [Related]
4. Impacts of Febuxostat on Cerebral and Cardiovascular Events in Elderly Patients with Hyperuricemia: Post Hoc Analysis of a Randomized Controlled Trial.
Sugawara M; Kojima S; Hisatome I; Matsui K; Uchiyama K; Yokota N; Tokutake E; Wakasa Y; Hiramitsu S; Waki M; Jinnouchi H; Kakuda H; Hayashi T; Kawai N; Mori H; Tsujita K; Ohya Y; Kimura K; Saito Y; Ogawa H;
Clin Pharmacol Ther; 2024 Jun; 115(6):1358-1364. PubMed ID: 38389505
[TBL] [Abstract][Full Text] [Related]
5. The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Hosoya T; Kimura K; Itoh S; Inaba M; Uchida S; Tomino Y; Makino H; Matsuo S; Yamamoto T; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H
Trials; 2014 Jan; 15():26. PubMed ID: 24433285
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
Oyama J; Tanaka A; Sato Y; Tomiyama H; Sata M; Ishizu T; Taguchi I; Kuroyanagi T; Teragawa H; Ishizaka N; Kanzaki Y; Ohishi M; Eguchi K; Higashi Y; Yamada H; Maemura K; Ako J; Bando YK; Ueda S; Inoue T; Murohara T; Node K;
Cardiovasc Diabetol; 2016 Jun; 15():87. PubMed ID: 27317093
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
[TBL] [Abstract][Full Text] [Related]
8. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
MacDonald TM; Ford I; Nuki G; Mackenzie IS; De Caterina R; Findlay E; Hallas J; Hawkey CJ; Ralston S; Walters M; Webster J; McMurray J; Perez Ruiz F; Jennings CG;
BMJ Open; 2014 Jul; 4(7):e005354. PubMed ID: 25011991
[TBL] [Abstract][Full Text] [Related]
9. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
[TBL] [Abstract][Full Text] [Related]
10. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
Gunawardhana L; McLean L; Punzi HA; Hunt B; Palmer RN; Whelton A; Feig DI
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29102979
[TBL] [Abstract][Full Text] [Related]
11. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
[TBL] [Abstract][Full Text] [Related]
12. Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study.
Tani S; Nagao K; Hirayama A
Clin Drug Investig; 2015 Dec; 35(12):823-31. PubMed ID: 26482071
[TBL] [Abstract][Full Text] [Related]
13. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
14. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
15. Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Kohagura K; Kojima S; Uchiyama K; Yokota N; Tokutake E; Wakasa Y; Hiramitsu S; Waki M; Jinnouchi H; Kakuda H; Hayashi T; Kawai N; Sugawara M; Mori H; Tsujita K; Matsui K; Hisatome I; Ohya Y; Kimura K; Saito Y; Ogawa H;
Hypertens Res; 2023 Jun; 46(6):1417-1422. PubMed ID: 36750608
[TBL] [Abstract][Full Text] [Related]
16. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Lee JW; Lee KH
Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
[TBL] [Abstract][Full Text] [Related]
17. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
[TBL] [Abstract][Full Text] [Related]
18. Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trial.
Kojima S; Uchiyama K; Yokota N; Tokutake E; Wakasa Y; Hiramitsu S; Waki M; Jinnouchi H; Kakuda H; Hayashi T; Kawai N; Sugawara M; Mori H; Tsujita K; Matsui K; Hisatome I; Ohya Y; Kimura K; Saito Y; Ogawa H;
Rheumatology (Oxford); 2022 May; 61(6):2346-2359. PubMed ID: 34605897
[TBL] [Abstract][Full Text] [Related]
19. Effect of the Xanthine Oxidase Inhibitor, Febuxostat, on WBC Count in Asymptomatic Hyperuricemia: Subanalysis of the Randomized PRIZE Study.
Takeshita M; Tanaka A; Yoshida H; Nakamura I; Shibata Y; Hata S; Kushiyama A; Okutsu M; Ishizu T; Node K
J Atheroscler Thromb; 2024 Jun; 31(6):864-875. PubMed ID: 38220209
[TBL] [Abstract][Full Text] [Related]
20. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
Yang AY
Int J Clin Pharmacol Ther; 2020 Jan; 58(1):21-28. PubMed ID: 31657714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
